Online inquiry

IVTScrip™ mRNA-Anti-CTLA4, CP-675(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6133MR)

This product GTTS-WQ6133MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CTLA4 gene. The antibody can be applied in Melanoma research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001037631.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1493
UniProt ID P16410
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CTLA4, CP-675(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ6133MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9996MR IVTScrip™ mRNA-Anti-FGF23, KRN-23(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA KRN-23
GTTS-WQ4705MR IVTScrip™ mRNA-Anti-MAPT, BMS-986168(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BMS-986168
GTTS-WQ12933MR IVTScrip™ mRNA-Anti-MUC1, PankoMab(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PankoMab
GTTS-WQ8945MR IVTScrip™ mRNA-Anti-IL1RL2, IL2 fused to diphteria toxin(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA IL2 fused to diphteria toxin
GTTS-WQ12218MR IVTScrip™ mRNA-Anti-TNFRSF4, MOXR-0916(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MOXR-0916
GTTS-WQ888MR IVTScrip™ mRNA-Anti-PDCD1, ABBV-181(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABBV-181
GTTS-WQ2315MR IVTScrip™ mRNA-Anti-CD200, ALXN6000(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ALXN6000
GTTS-WQ13239MR IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA PF-05335810
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW